Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

Bristol Myers Squibb (BMY) and partner 2seventy bio, Inc (TSVT) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor of Abecma’s (idecabtagene vicleucel) benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM).Abecma is a chimeric antigen receptor (CAR) T-cell therapy, already indicated for adult patients with triple-class exposed RRMM after four or more prior lines of treatment, including an immunomodulatory agent, a proteasome i ...